

# Effectiveness of recombinant *Escherichia coli* for the production of (*R*)-(+)-perillyl alcohol

**Chao Sun**

Qingdao University of Science and Technology

**Xianjuan Dong**

Qingdao Institute of BioEnergy and Bioprocess Technology Chinese Academy of Sciences

**Rubing Zhang** (✉ [zhangrb@qibebt.ac.cn](mailto:zhangrb@qibebt.ac.cn))

Qingdao Institute of BioEnergy and Bioprocess Technology Chinese Academy of Sciences

<https://orcid.org/0000-0003-0985-7900>

**Congxia Xie**

Qingdao University of Science and Technology

---

## Research

**Keywords:** Limonene, Perillyl alcohol, *Escherichia coli*, Mevalonate pathway, Microbial production

**Posted Date:** February 8th, 2020

**DOI:** <https://doi.org/10.21203/rs.2.22908/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**Background:** (*R*)-(+)-perillyl alcohol is a naturally oxygenated monoterpene that is produced in perilla leaves, citrus, lemon and lavender. Perillyl alcohols have many uses, including natural flavor additives, insecticides, jet fuels and anti-cancer therapies. The bioconversion of readily available monoterpene precursors, such as (*R*)-(+)-limonene are recognized as valuable oxygenated derivatives. However, as this natural product is present at low concentrations in plant oils, alternative microbial production methods are required for its extraction from natural plant sources.

**Results:** In this study, we engineered *Escherichia coli* to possess a heterologous mevalonate (MVA) pathway, including limonene synthase, P-cymene monooxygenase hydroxylase and P-cymene monooxygenase reductase for the production of (*R*)-(+)-perillyl alcohol. The concentration of (*R*)-(+)-limonene (the monoterpene precursor to (*R*)-(+)-perillyl alcohol) reached 27.3 mg/L from glucose. Enhanced (*R*)-(+)-perillyl alcohol production was therefore achieved. The strain produced (*R*)-(+)-perillyl alcohol at a titer of 45.7 mg/L in a 5 L bioreactor fed batch system.

**Conclusions:** These data highlight the efficient production of (*R*)-(+)-perillyl alcohol through microbial fermentation. This can serve as a platform for the future production of other monoterpenes.

## Background

Perillyl alcohol is a natural monoterpene that exists in two optical forms. (*R*)-(+)-perillyl alcohol is produced in perilla leaves, citrus, lemon and lavender [1-3] and has extensive applications. It serves as a natural flavor additive for food, as an insecticide in agricultural fields, jet fuel in aviation fields, and as a healing agent for anti-cancer therapeutics [4-7]. The bioconversion of readily available monoterpene precursors (such as (*R*)-(+)-limonene) are recognized as more valuable oxygenated derivatives [8]. Up to 70%-97% of (*R*)-(+)-limonene is present in citrus oils [9] and is produced to levels that exceed 60000t per year [10]. Many terpenes are synthesized from limonene, such as perillyl alcohol, carvone and  $\alpha$ -terpineol. The enantiomers of carvone cost US \$ 30–60 per kg; whilst (*S*)-(-)- and (*R*)-(+)-perillyl cost US\$4500/kg [7,11]. As the chemical synthesis of perillyl alcohol is of high cost and leads to environmental pollution, the biosynthesis of perillyl alcohol from renewable carbon sources has been regarded as an economically feasible industrial process. New and more effective synthesis procedures are however required.

While (*R*)-(+)-perillyl alcohol can be synthesized in *Escherichia coli* [12,13], *Pseudomonas putida* [5,14-18], *Yarrowia lipolytica* [17,19], *Mortierella minutissima* [20], *Fusarium verticilloides* [21], *Aspergillus* strain [22,23]. All of these microorganisms can biotransform limonene to perillyl alcohol. It has been reported that *Bacillus pallidus* BR425 [24] can be used during the synthesis of perillyl alcohol with  $\alpha$ -pinene as the substrate. Metabolic engineering for natural compound production can be enhanced through gene modifications that increase enzyme activity. During (*S*)-(-)-perillyl alcohol production, titers can be increased to up to 100 mg/L for *Escherichia coli* [12]. Many terpenoids have been produced at high titers by metabolic engineering, including monoterpenes, sesquiterpenes, diterpenes and tetraterpenes [25-34].

Isopentenyl diphosphate (IPP) and its isomer dimethylallyl diphosphate (DMAPP) form the building blocks of monoterpenes, sesquiterpenes, and diterpenes during synthesis, the precursors of which include geranyl pyrophosphate (GPP), farnesylpyrophosphate (FPP), and geranylgeranyl pyrophosphate (GGPP), respectively. These precursors are derived from mevalonate (MVA) and are catalyzed by geranyl pyrophosphate diphosphate synthase (GPPS) (Fig. 1). However, the microbial mediated production of monoterpenes is limited by toxicity [35] and poor GPPS expression [36,37]. In this study, we engineered *E. coli* to produce (*R*)-(+)-perillyl alcohol from glucose by heterologous expression of P-cymene monooxygenase hydroxylase (CymAa) and a P-cymene monooxygenase reductase (CymAb) (Fig. 1). Genetic modifications to enhance the production of (*R*)-(+)-perillyl alcohol including were performed. These included the codon optimization of *cymAa*, *cymAb* and *CILS* and exogenous GPPS expression. The highest performing strain SC04 was then cultured under fed-batch conditions for the assessment of its potential for large-scale production.

## Results

### Characterization of perillyl alcohol by GC-MS

It is well established that during (*S*)-(-)-perillyl alcohol production, titers can be increased by 100 mg/L using *Escherichia coli* [12]. Many terpenoids have been produced to high titers through metabolic engineering, including monoterpenes, sesquiterpenes, diterpenes and tetraterpenes [25–34]. In this study, P-cymene monooxygenase hydroxylase (CymAa) and P-cymene monooxygenase reductase (CymAb) derived from *Pseudomonas putida* were introduced into BL21 (DE3) [15, 18]. Recombinant monoterpene synthase was used with (*R*)-(+)-limonene as the substrate in in vitro enzyme assays. (*R*)-(+)-limonene exists in more than 70% of the citrus fruits. Limonene, one of the simplest monoterpenes, has a chiral center, appearing (*R*)-(+)- and (*S*)-(-), respectively [38]. CymAa and cymAb were ligated into pET28a (+) to create the plasmid pSC01. BL21 (DE3) containing pSC01 was inoculated in 250 ml sealed flasks at 37 °C with shaking. At an OD<sub>600</sub> of 0.6, IPTG and (*R*)-(+)-limonene were added for 24 h at 30 °C. Products were identified by GC-MS after organic extraction by ethyl acetate. As shown in Fig. S1, control assays with extracts of *E. coli* lacking a cDNA clone did not yield (*R*)-(+)-perillyl alcohol, *E. coli* strain carrying *cymAa* and *cymAb* from *Pseudomonas putida* produced (*R*)-(+)-perillyl alcohol to detectable quantities. The biosynthetic pathway for (*R*)-(+)-perillyl alcohol production was successfully constructed using (*R*)-(+)-limonene as a substrate.

### Perillyl alcohol production from limonene

Limonene is toxic to most microorganisms and its concentrations regulate the growth of BL21 (DE3).

It was therefore important to assess the optimal concentrations of limonene for fed-batch production. Different (*R*)-(+)-limonene concentrations were assessed (0.2 mM to 3 mM) in growth assays (Fig. 2). When (*R*)-(+)-limonene was used at 0.2 mM, the maximum conversion yield of perillyl alcohol was 58%. When (*R*)-(+)-limonene was used at 2 mM, the maximum production was 86.9 mg/L. When limonene was used at  $\geq 2$  mM, the production and yield of (*R*)-(+)-perillyl alcohol decreased. At increased limonene

concentrations, cell growth declined. At (R)-(+)-limonene concentrations of 1.0 mM, the  $OD_{600}$  decreased from 2.5 to 2.0. SC01 could catalyze the synthesis of (R)-(+)-perillyl alcohol using (R)-(+)-limonene as the substrate. The optimum limonene concentration was therefore 0.2 mM.

## Limonene production from glucose

We optimized the yields of limonene to improve the production of perillyl alcohol. pTrcHis2B and pET-28a(+) were assessed. pYJM14 contains ERG8, ERG19, IDI from *Saccharomyces cerevisiae* [39]. pSC02 contains geranyl pyrophosphate synthase GPPS from *Abies grandis* that converts the IPP/DMAPP to GPP and (R)-(+)-limonene synthase CILS from citrus limon that converts GPP to limonene [40] (Table 1). SC02 was cultured in fermentation medium under sealed shake-flask conditions.

Table 1  
Strains and plasmids used in this study

Name	Relevant characteristics	References
Strains		
E.coli DH5 $\alpha$	F <sup>-</sup> recA endA1 $\Phi$ 80dlacZ $\Delta$ M15hsdR17(r <sub>k</sub> <sup>-</sup> m <sub>k</sub> <sup>+</sup> ) $\lambda$ <sup>-</sup>	Invitrogen
E.coli BL21(DE3)	F- ompT hsdSB (rB - mB - ) gal dcm rne131 $\lambda$ (DE3)	Invitrogen
SC01	E.coli BL21(DE3)/pSC01	This study
SC02	E.coli BL21(DE3)/pSC02,pYJM14	This study
SC03	E.coli BL21(DE3)/pSC03	This study
SC04	E.coli BL21(DE3)/pSC04,pYJM14	This study
SC05	E.coli BL21(DE3)/pSC05,pYJM14	This study
Plasmids		
pTrcHis2B	pBR322 origin, Amp	Invitrogen
pET28a(+)	Kan <sup>r</sup> oripBR322lacI <sup>q</sup> T7p	Novagen
pCOLADuet-1	Kan <sup>r</sup> ColA lacI T7lac	Novagen
pYJM14	pTrcHis2B carrying ERG12, ERG8, ERG19 and IDI from <i>Saccharomyces cerevisiae</i>	[39]
pSC01	pET28a(+)carring cymAa and cymAb from <i>Pseudomonas putida</i>	This study
pSC02	pET28a(+)carrying mvaE and mvaS from <i>Enterococcus faecalis</i> , ,GPPS from <i>Abies grandis</i> ,CILS from <i>Citrus limon</i> .	This study
pSC03	pET28a(+) carrying GPPS from <i>Abies grandis</i> ,CILS from <i>Citrus limon</i> .	This study
pSC04	pET28a(+)carrying mvaE and mvaS from <i>Enterococcus faecalis</i> ,,GPPS from <i>Abies grandis</i> ,CILS from <i>Citrus limon</i> , cymAa and cymAb from <i>Pseudomonas putida</i>	This study
pSC05	pCOLADuet-1-carrying mvaE and mvaS from <i>Enterococcus faecalis</i> , ,GPPS from <i>Abies grandis</i> ,CILS from <i>Citrus limon</i> , cymAa and cymAb from <i>Pseudomonas putida</i>	Tis study

The levels of (R)-(+)-limonene in the culture media were plotted against known concentrations of (R)-(+)-limonene. The (R)-(+)-limonene concentration of SC02 reached 10.4 mg/L and 27.3 mg/L (milligram limonene per liter of culture) with 0.2 mM IPTG and 10% n-dodecane overlay at 48 h and 72 h after induction. When 10% DINP (diisononyl phthalate) was used instead of n-dodecane overlay, the limonene titers were 0.9 mg/L and 2.0 mg/L selectively at 48 h and 72 h (Fig. 3). The enantiomer forms produced

by the strain cultures were analyzed using GC with an Cyclosil-B column, and the production of (R)-(+)-limonene by SC02 was confirmed (Fig. S2).

## Microbial perillyl alcohol production using the MVA pathway

CymAa and CymAb catalyze the biosynthesis of (R)-(+)-perillyl alcohol using (R)-(+)-limonene as a direct substrate through a hydroxylated reaction at the 7 position. We cloned cymAa and cymAb from *Pseudomonas putida* into pSC04&pSC05. Terpenoid synthase is expressed to low levels in *E. coli* [41] so cymA and cymAb were codon optimized (Table 1). According to the analysis of chirality of the intermediate limonene produced by the strain SC02, we concluded that the configuration of perillyl alcohol was determined to be R-type (Fig. S2). The expression levels in the perillyl alcohol pathway in the strain SC04 were investigated by qRT-PCR. The results indicated that genes, ERG8, ERG19, ERG12, IDI significantly increase compared with the control. Moreover, genes mvaE, mvaS, CILS, GPPS, cyma and cymAb were not obvious compared with the control (Fig. 4). We used n-dodecane or DINP as the extraction solvent and the organic phase was collected and centrifuged to remove cell contaminants. Samples were then subjected to GC-MS analysis and trace levels of perillyl alcohol were detected. pYJM14 and pSC04&pSC05 were co-transformed into *E. coli* BL21 (DE3), resulting in recombinant strain SC04&SC05. SC04 was cultured in sealed shake flasks to assess perillyl alcohol production. (R)-(+)-perillyl alcohol level for SC04 reached 5.2 mg/L after induction by 0.2 mM IPTG and 10% DINP overlay for 72 h, which was 2.4-fold higher than strain SC05 (2.1 mg/L for 72 h) (supplementary Fig. 5). In the absence of DINP, SC04 produced 0.6 mg/L and 0.4 mg/L of perillyl alcohol. We included n-dodecane overlay in the cultures, and thus no perillyl alcohol was detected [12]. The production of perillyl alcohol was 0.6 mg/L in SC04 and 0.4 mg/L in SC05, mainly due to the rapid extraction of limonene to the organic phase, and as n-dodecane overlay cannot be used for perillyl alcohol fermentation.

## Fed-batch culture of engineered E.coli strains

High cell densities for (R)-(+)-perillyl alcohol production were achieved through fed-batch fermentation using SC04 in a 5 L bioreactor. According to the residual glucose concentrations, feeding rates were maintained at  $\leq 1$  g/L. Figure 6 shows the time-course of (R)-(+)-perillyl alcohol production and cell density during fermentation. (R)-(+)-perillyl alcohol biosynthesis was initiated from 5 h of induction and 10% DINP was added during the fed-batch process. After 60 h of cultivation, the production of (R)-(+)-perillyl alcohol peaked at 45.7 mg/L with DINP overlay. However, the engineered strain achieved a cell-density  $OD_{600}$  of 108 for two-phase fermentation. The accumulation of IPP and DMAPP may have influenced the growth of the engineered strain [29, 42, 43]. However, the two-phase fermentation of (R)-(+)-perillyl alcohol fermentation can eliminate toxic intermediates. (R)-(+)-perillyl alcohol biosynthesis requires an array of genes which when overexpressed, can influence host cell viability and reduce productivity [44].

## Discussion

(R)-(+)-perillyl alcohol is produced in perilla leaves, citrus, lemon and lavender and has a range of valuable applications. Many terpenes are synthesized from limonene, such as perillyl alcohol, carvone and  $\alpha$ -terpineol. Because the chemical synthesis of perillyl alcohol is of high cost and environmentally unfriendly, the biosynthesis of perillyl alcohol from renewable carbon sources has been regarded as an economically feasible industrial process. Indeed, the development of (R)-(+)-perillyl alcohol as an anti-cancer drug has been limited by the costs associated with extracting the compound from its natural oil. Terpenes are produced by microorganisms and can be scaled-up to increase drug production [45]. Here, we used *E. coli* as a host and confirmed the feasibility of (R)-(+)-perillyl alcohol production. The levels produced were however, too low for industrial requirements.

(R)-(+)-perillyl alcohol synthesis requires CymAa and CymAb. Both convert limonene and are derived from the metabolic pathway of p-cymene [15]. Enzyme activity was lower than many other terpene synthases, that can reduce perillaldehyde or perilla acid [18]. We initially engineered the strain SC0 and showed successful (R)-(+)-perillyl alcohol production using GC-MS (Fig. S1). The maximum production of (R)-(+)-perillyl alcohol which was composed with (R)-(+)-limonene as substrate was 86.9 mg/L and lethal concentrations of limonene to *E. coli* were 2 mM (Fig. 2). (R)-(+)-Limonene accumulates in biological membranes leading to membrane damage in microorganisms, which is insoluble in water [46]. It has been reported that limonene is inhibitory to multiple microorganisms [47]. A recent report [48] revealed that 0.025% (v/v) limonene inhibited the growth of *E. coli* [35]. Thus, the tolerance and solubility of limonene requires improvements to increase both the concentrations and yields of (R)-(+)-perillyl alcohol.

In previous studies, terpenoids have been studied using the MVA pathway [25, 29, 30, 49]. Our research group constructed engineered *E. coli* which synthesized isoprene by the mevalonate (MVA) pathway and produced isoprene 665.2 mg/L under flask conditions [50, 51]. GPPS and CILS were engineered to improve (R)-(+)-limonene production, and SC03 produced no detectable limonene (data not shown), highlighting the need for terpenes. When no extracts were added during limonene fermentation, no detectable SC02 was observed (data not known), indicating that limonene is rapidly lost from the culture medium. As limonene from the fermentation system was highly volatile and anti-microbial [52, 53] other collection methods have been reported including culture extraction, solvent overlay, solid-phase micro-extraction, gas shipping to a cold trap and adsorbent polydimethylsiloxane bars [52, 54, 55]. Whilst not all of these methods are appropriate, they can prevent product inhibition and toxicity, avoiding evaporative loss of the limonene product using the two-phase system. Davies et al. [56] showed that an overlay of n-dodecane enhanced limonene recovery. N-dodecane was selected as a favorable solvent for terpenoid extraction experiments due to its low volatility [56]. In engineered *E. coli*, DINP fermentation prolongs both growth and production phases, leading to (S)-(-)-limonene concentrations of 1.35 g/L [57]. (R)-(+)-limonene obtained by n-dodecane extraction was 27.3 mg/L for 72 h, 3-fold higher than DINP extraction (Fig. 3). It may be that the distribution coefficient of (R)-(+)-limonene in n-octane is larger than that in the DINP phase. At the same time, the strain fermented by DINP overlay inhibited the growth of cells, and the OD<sub>600</sub> decreases from 3.4 to 2.5 (Fig. 3). Jongedijk et al. [52] engineered *Saccharomyces cerevisiae* to express (R)-(+)-limonene synthase from *Citrus limon*. Trapping of the headspace in limonene synthase

expressing strains results in 0.12 mg/L (R)-(+)-limonene. Pang et al. [58] engineered *Yarrowia lipolytica* to achieve (R)-(+)-limonene at 11.705 mg/L, through the overexpression of HMGR and the optimization of fermentation conditions. Cao et al. [59] engineered *Yarrowia lipolytica* to increase limonene titers to 23.56 mg/L by encoding neryl diphosphate synthase1 (NDPS1) and limonene synthase (LS). Here, we engineered *E. coli* to produce (R)-(+)-limonene to 27.3 mg/L, close to the maximum titers reported.

We confirmed the chirality of perillyl alcohol was (R)-type in SC04, which was conducted with (R)-(+)-limonene as an intermediate (Fig. S2). We then engineered SC04 & SC05 and investigated the effects of copy numbers on (R)-(+)-perillyl alcohol production. We hypothesized that *cymAa* and *cymAb* genes produced by the lower copies of SC05 could not repress all promoters. In contrast, SC04 strain had 40 copies encoding the repressor on medium and middle-copy plasmids. The genes contributed to higher levels in SC04 than in SC05 (Fig. 4). This hypothesis was supported by the production of perillyl alcohol, which was 2.4-fold in SC04 and SC05 (from 2.1 mg/L to 5.2 mg/L) (Fig. 5). In addition, the levels of ERG12, ERG8, and ERG19 in the MVA pathway were higher than the control strain, whilst the levels of GPPS, CILS, *cymAa*, and *cymAb* showed no obvious changes compared to controls (Fig. 4). Most intermediates can be efficiently converted to IPP, but the production from IPP to perillyl alcohol was weak. This suggests that we can enhance the production of (R)-(+)-perillyl alcohol through regulating metabolic imbalances.

## Conclusions

In summary, (R)-(+)-perillyl alcohol production was achieved by assembling biosynthetic genes encoding a heterologous MVA pathway. The highest-performing strain SC04 accumulated up to 45.7 mg/L of (R)-(+)-perillyl alcohol under fed-batch fermentation conditions. This study provides a platform for the synthesis of monoterpenes. Efforts should now be directed towards the optimization of the mevalonate pathway.

## Methods

### Strains and culture conditions

Metabolic engineering for natural compound production can be enhanced through gene modifications that increase enzyme activity. All experimental materials used in this study are listed in Table 1. *E. coli* were grown in LB (tryptone 10 g/L, yeast extract 5 g/L and NaCl 10 g/L). During the production of (R)-(+)-limonene and (R)-(+)-perillyl alcohol, strains were cultivated in shake-flasks in medium containing glucose 10 g/L, MgSO<sub>4</sub> 1 mM and riboflavin 0.05 mM during fed-batch fermentation in glucose 20 g/L, K<sub>2</sub>HPO<sub>4</sub> 9.8 g/L, ferric ammonium citrate 0.3 g/L, citric acid monohydrate 2.1 g/L, MgSO<sub>4</sub> 1 mM, riboflavin 0.05 mM and 1 mL trace element solution, including (NH<sub>4</sub>)<sub>6</sub>Mo<sub>7</sub>O<sub>24</sub>·4H<sub>2</sub>O 0.37 g/L, ZnSO<sub>4</sub>·7H<sub>2</sub>O 0.29 g/L, H<sub>3</sub>BO<sub>4</sub> 2.47 g/L, CuSO<sub>4</sub>·5H<sub>2</sub>O 0.25 g/L, and MnCl<sub>2</sub>·4H<sub>2</sub>O 1.58 g/L. As required, ampicillin (100 µg/ml) and kanamycin (50 µg/ml) were added to the culture media for selection.

# Plasmids construction

P-cymene monooxygenase hydroxylase (cymAa, GenBank Accession No.:AAB62299.1) and P-cymene monooxygenase reductase (cymAb, GenBank Accession No.:AAB62300.1) from *Pseudomonas putida* were codon optimized on ([www.jcat.de](http://www.jcat.de)), and cloned into pUC57. CymAa and cymAb were PCR amplified and subcloned into pET28a (+) with BamHI/SacI restriction sites, creating pSC01 (pET28a-cymAa-cymAb). CILS (GenBank Accession No.:AF514287.1) of Citrus limon and GPPS (GenBank Accession No.:AF513112.1) of *Abies grandis* were amplified and ligated into pUC57 using Genewiz Biotech Co., Ltd. (Suzhou, China), producing pUC57-CILS&pUC57-GPPS. MvaE-mvaS was then excised from pYJM20 [50] and ligated onto pET-28a (+) to create pET28a-mvaE-mvaS. GPPS and CILS were cloned and assembled into pET28a-mvaE-mvaS at the SacI/AatII sites to generate pSC02 (Table 1). CymAa-cymAb fragments were obtained through *Pseudomonas putida* using AatII and PacI and ligated into pSC02 to create pSC03 (Table 1). MvaE, mvaS, and GPPS were cloned from pSC02 into pCOLADuet-1 at the BamHI/XhoI sites, generating pcolaDuet-mvaE-mvaS-GPPS-CILS. CymAa, cymAb were cloned from pSC03 into pcolaDuet-mvaE-mvaS-GPPS-CILS at the XhoI/PacI sites to produce pSC05 (Table 1).

pYJM14 was constructed from pTrcHis2B through the introduction of ERG8, ERG12, ERG19 and IDI from *S. cerevisiae* [39, 60]. All plasmids and primers are shown in Table S1.

## RT-PCR analysis

Total RNA was isolated from 24 h cultures using commercially available SPAKeasy RNA kits. RNA was reverse transcribed using TaKaRa Primer Script RT reagent Kit and RT-PCRs were performed. Each reaction contained 1  $\mu$ L cDNA, 5 $\mu$ L TB green Premix Ex TaqII, 0.2 $\mu$ L 50  $\times$  ROX Reference Dye, 0.2  $\mu$ M for/rev primer, and ddH<sub>2</sub>O up to 10  $\mu$ L. RT-PCR conditions were as follows: 30 s at 95  $^{\circ}$ C, 40 cycles of 95  $^{\circ}$ C for 5 s, 60  $^{\circ}$ C for 30 s. Gene expression was normalized to absolute transcript levels of rpoD. qRT-PCRs was performed on a Primer 5.0 program (Table S2). Relative gene expression was calculated using the  $2^{-\Delta\Delta C_t}$  method for each treatment. Reactions were repeated at least 3 times.

## Shake-flask fermentation

Cultures were produced in 25 ml of LB. *E. coli* strains with each recombinant plasmid were inoculated in a gyratory shaker at 37  $^{\circ}$ C and 180 rpm. IPTG (0.2 mM) was added to induce recombinant protein expression upon an OD<sub>600</sub> of 0.6. Cultures were incubated at 30  $^{\circ}$ C with 2-phase fermentation [61] used for limonene and perillyl alcohol extraction from the aqueous broth due to the toxicity of terpenes. We added 10% (v/v) n-dodecane or DINP (disononyl phthalate) following IPTG induction and cultures were incubated for 72 h. Cell densities, glucose levels, limonene levels and perillyl alcohol production were then assessed.

## Fed-batch fermentation

For (R)-(+)-perillyl alcohol production at a larger scale, fed-batch cultivations were performed in a 5 L bioreactor system (Biostat B plus MO 5L) using 2 L of fermentation fluid. Seed cultures (100 ml, 10 g

NaCl, 5 g yeast extract, and 10 g of tryptone per 1 L) were added to shake flasks overnight at 37 °C and Sparger aeration was performed to maintain high dissolved oxygen (DO) levels. Post-fermentation, the pH of the broth was maintained at 7.0 through ammonia addition. Fermentation was performed during the growth stage under the following conditions: 37 °C, agitation 400 rpm and airflow at 1 L/min. Antifoam 204 was added as required. DO was maintained at 20% saturation through the control of air flow and stirrer speed (1–2 L/min and 400–900 rpm, respectively). When cells reached an OD<sub>600</sub> of ~ 20, the temperature was switched to 30 °C and 0.2 mM IPTG and 0.05 mM riboflavin were added. DINP (10%) was added after 4 h and initial glucose levels were exhausted, as indicated by the increase in DO. The fed batch mode was initiated through the feeding of 60% glucose at appropriate rates. Residual glucose levels were maintained to low levels through the addition of acetic acid. Samples were periodically collected and OD<sub>600</sub> values were determined prior to centrifugation for the separation of organic and aqueous phases. Organic layers were removed for all GC–MS analysis.

## Analytical methods

*E. coli* growth was determined through OD<sub>600</sub> measurements on a spectrophotometer (Cary 50 UV-vis, Varian). The Shimadzu GC-MS system (TQ8050) was used for Limonene and perillyl alcohol identification. GC-MS conditions were as follows: 30 m DB-5MS column (internal diameter 0.32 mm, film thickness 0.25 µm); temperature: 50 °C hold, ramped up 10 °C/min to 250 °C with a final hold at 250 °C for 10 min. Highly pure helium as a carrier was used at a linear velocity of 1 ml/min; an injector temperature of 250 °C; a split ratio of 1:10; an ion source temperature of 230 °C and mass range of m/z 40–500. Limonene and perillyl alcohol peaks were identified through the retention times of external standards and MS comparisons via the National Institute of Standards and Technology (NIST) database. Fermentation broths were mixed, centrifuged, and the organic layer was taken for GC-MS analysis.

The enantiomeric distribution of limonene was analyzed using the Agilent Technologies 7890B GC System on a Cyclodex B column (30m × 0.25 mm internal diameter; film thickness = 0.25 µm). GC conditions were as follows: 50 °C hold, 2 °C/min ramping to 160 °C; carrier: high-purity helium, linear velocity: 1 ml/min; temperature of the injector: 250 °C; split ratio: 1:20. Compounds of interest: (S)-(-)-limonene at 21.2 min and (R)-(+)-limonene at 22.02 min. The fermentation broth was mixed and centrifuged, and the organic layer was analyzed.

## Declarations

## Ethics approval and consent to participate

Not applicable

## Availability of data and materials

The data supporting the conclusions of this article are included within the article.

## Competing interests

The authors declare that they have no competing interests.

## Funding

This work was supported by the National Natural Science of China (grant number 21878166), and the Taishan Scholar Project of Shandong Province, China (grant number ts201511033)

## Authors' contributions

CS, RZ and CX conceived and designed research. XD contributed analytical tools. CS performed experiments and analyzed data. CS wrote the manuscript. All authors read and approved the manuscript.

## Acknowledgements

The authors appreciate the contribution of the Dr. Yujin Cao for his advice on strain design. The authors also acknowledge Cong Wang for the assistance on the conduction of GC-MS.

## References

1. Peterson A, Bansal A, Hofman F, Chen TC, Zada G. A systematic review of inhaled intranasal therapy for central nervous system neoplasms: an emerging therapeutic option. *J Neuro-Oncol.* 2014;116:437–46.
2. Sundin T, Peffley D, Hentosh P. eIF4E-Overexpression imparts perillyl alcohol and rapamycin-mediated regulation of telomerase reverse transcriptase. *Exp Cell Res.* 2013;319:2103–12.
3. Sundin T, Peffley DM, Gauthier D, Hentosh P. The isoprenoid perillyl alcohol inhibits telomerase activity in prostate cancer cells. *Biochimie.* 2012;94:2639–48.
4. Bindu PC, Jaisankar P, Hauer F, Gutzeit HO, Kundu SC. Biological relevance of host plant-derived terpenoid in the cocoons of the tropical tasar silkworm *Antheraea mylitta*. *Biochem Syst Ecol.* 2006;34:698–704.
5. Duetz WA, Bouwmeester H, Van Beilen JB, Witholt B. Biotransformation of limonene by bacteria, fungi, yeasts, and plants. *Appl Microbiol Biotechnol.* 2003;61:269–77.
6. Paduch R, Kandefer-Szerszeń M, Trytek M, Fiedurek J. Terpenes: substances useful in human healthcare. *Arch Immunol Ther Exp.* 2007;55:315.

7.  
Wagner KH, Elmadfa I. Biological relevance of terpenoids. *Ann Nutr Metab.* 2003;47:95–106.
8.  
De Carvalho CC, da Fonseca MM. Biotransformation of terpenes. *Biotechnol Adv.* 2006;24:134–42.
9.  
Tranchida PQ, Zoccali M, Bonaccorsi I, Dugo P, Mondello L, Dugo G. The off-line combination of high performance liquid chromatography and comprehensive two-dimensional gas chromatography-mass spectrometry: a powerful approach for highly detailed essential oil analysis. *J Chromatogr A.* 2013;1305:276–84.
10.  
Lange BM. Biosynthesis and biotechnology of high-value p-menthane monoterpenes, including menthol, carvone, and limonene. In: Schrader J, Bohlmann J, editors. *Biotechnology of Isoprenoids. Advances in Biochemical Engineering/Biotechnology.* Cham: Springer; 2015. pp. 319–53.
11.  
van Beilen JB, Holtackers R, Lüscher D, Bauer U, Witholt B, Duetz WA. Biocatalytic production of perillyl alcohol from limonene by using a novel *Mycobacterium* sp. cytochrome P450 alkane hydroxylase expressed in *Pseudomonas putida*. *Appl Environ Microbiol.* 2005;71:1737–44.
12.  
Alonso-Gutierrez J, Chan R, Batth TS, Adams PD, Keasling JD, Petzold CJ, Lee TS. Metabolic engineering of *Escherichia coli* for limonene and perillyl alcohol production. *Metab Eng.* 2013;19:33–41.
13.  
Chang HC, Gage DA, Oriel PJ. Cloning and expression of a limonene degradation pathway from *Bacillus stearothermophilus* in *Escherichia coli*. *J Food Sci.* 1995;60:551–3.
14.  
Chatterjee T, Bhattacharyya D. Biotransformation of limonene by *Pseudomonas putida*. *Appl Microbiol Biotechnol.* 2001;55:541–6.
15.  
Mars A, Gorissen J, Van Den Beld I, Eggink G. Bioconversion of limonene to increased concentrations of perillic acid by *Pseudomonas putida* GS1 in a fed-batch reactor. *Appl Microbiol Biotechnol.* 2001;56:101–7.
16.  
Mirata MA, Heerd D, Schrader J. Integrated bioprocess for the oxidation of limonene to perillic acid with *Pseudomonas putida* DSM 12264. *Process Biochem.* 2009;44:764–71.
17.  
Speelmans G, Bijlsma A, Eggink G. Limonene bioconversion to high concentrations of a single and stable product, perillic acid, by a solvent-resistant *Pseudomonas putida* strain. *Appl Microbiol Biotechnol.* 1998;50:538–44.
18.  
Willrodt C, Halan B, Karthaus L, Rehdorf J, Julsing MK, Buehler K, Schmid A. Continuous multistep synthesis of perillic acid from limonene by catalytic biofilms under segmented flow. *Biotechnol Bioeng.*

2017;114:281–90.

19.

Ferrara MA, Almeida DS, Siani AC, Lucchetti L, Lacerda PS, Freitas A, Tappin MR, Bon EP. Bioconversion of R-(+)-limonene to perillic acid by the yeast *Yarrowia lipolytica*. *Braz J Microbiol*. 2014;44:1075–80.

20.

Trytek M, Fiedurek J, Skowronek M. Biotransformation of (R)-(+)-Limonene by the psychrotrophic fungus *Mortierella minutissima* in H<sub>2</sub>O<sub>2</sub>-oxygenated culture. *Food Technol Biotechnol*. 2009;47:131–6.

21.

de Oliveira BH, Strapasson RA. Biotransformation of the monoterpene, limonene, by *Fusarium verticilloides*. *Braz Arch Biol Technol*. 2000;43:1–4.

22.

Menéndez P, García C, Rodríguez P, Moyna P, Heinzen H. Enzymatic systems involved in D-limonene biooxidation. *Braz Arch Biol Technol*. 2002;45:111–4.

23.

Noma Y, Yamasaki S, Asakawa Y. Biotransformation of limonene and related compounds by *Aspergillus cellulosa*. *Phytochemistry*. 1992;31:2725–7.

24.

Savithiry N, Gage D, Fu W, Oriel P. Degradation of pinene by *Bacillus pallidus* BR425. *Biodegradation*. 1998;9:337–41.

25.

Anthony JR, Anthony LC, Nowroozi F, Kwon G, Newman JD, Keasling JD. Optimization of the mevalonate-based isoprenoid biosynthetic pathway in *Escherichia coli* for production of the anti-malarial drug precursor amorpha-4,11-diene. *Metab Eng*. 2009;11:13–9.

26.

Dueber JE, Wu GC, Malmirchegini GR, Moon TS, Petzold CJ, Ullal AV, Prather KL, Keasling JD. Synthetic protein scaffolds provide modular control over metabolic flux. *Nat Biotechnol*. 2009;27:753–9.

27.

Matthäus F, Ketelhot M, Gatter M, Barth G. Production of lycopene in the non-carotenoid-producing yeast *Yarrowia lipolytica*. *Appl Environ Microbiol*. 2014;80:1660–9.

28.

Liu XB, Liu M, Tao XY, Zhang ZX, Wang FQ, Wei DZ. Metabolic engineering of *Pichia pastoris* for the production of dammarenediol-II. *J Biotechnol*. 2015;216:47–55.

29.

Martin VJJ, Pitera DJ, Withers ST, Newman JD, Keasling JD. Engineering a mevalonate pathway in *Escherichia coli* for production of terpenoids. *Nat Biotechnol*. 2003;21:796–802.

30.

Peralta-Yahya PP, Ouellet M, Chan R, Mukhopadhyay A, Keasling JD, Lee TS. Identification and microbial production of a terpene-based advanced biofuel. *Nat Commun*. 2011;2:483.

31.

- Trikka FA, Nikolaidis A, Athanasakoglou A, Andreadelli A, Ignea C, Kotta K, Argiriou A, Kampranis SC, Makris AM. Iterative carotenogenic screens identify combinations of yeast gene deletions that enhance sclareol production. *Microb Cell Fact*. 2015;14:60.
- 32.
- Tsuruta H, Paddon CJ, Eng D, Lenihan JR, Horning T, Anthony LC, Regentin R, Keasling JD, Renninger NS, Newman JD. High-level production of amorpha-4,11-diene, a precursor of the antimalarial agent artemisinin, in *Escherichia coli*. *PLoS One*. 2009;4:e4489.
- 33.
- Wu J, Cheng S, Cao J, Qiao J, Zhao GR. Systematic optimization of limonene production in engineered *Escherichia coli*. *J Agric Food Chem*. 2019;67:7087–97.
- 34.
- Yoon SH, Lee SH, Das A, Ryu HK, Jang HJ, Kim JY, Oh DK, Keasling JD, Kim SW. Combinatorial expression of bacterial whole mevalonate pathway for the production of  $\beta$ -carotene in *E. coli*. *J Biotechnol*. 2009;140:218–26.
- 35.
- Dunlop MJ, Dossani ZY, Szmids H, Chu HC, Lee TS, Keasling JD, Hadi MZ, Mukhopadhyay A. Engineering microbial biofuel tolerance and export using efflux pumps. *Mol Syst Biol*. 2011;7:487.
- 36.
- Carter OA, Peters RJ, Croteau R. Monoterpene biosynthesis pathway construction in *Escherichia coli*. *Phytochemistry*. 2003;64:425–33.
- 37.
- Reiling KK, Yoshikuni Y, Martin VJ, Newman J, Bohlmann J, Keasling JD. Mono and diterpene production in *Escherichia coli*. *Biotechnol Bioeng*. 2004;87:200–12.
- 38.
- Sawamura M. Volatile components of essential oils of the citrus genus. *Recent Res Dev Agric Food Chem*. 2000;4:131–64. [42].
- 39.
- Yang J, Zhao G, Sun Y, Zheng Y, Jiang X, Liu W, Xian M. Bio-isoprene production using exogenous MVA pathway and isoprene synthase in *Escherichia coli*. *Bioresour Technol*. 2012b;104:642–7.
- 40.
- Lücker J, El Tamer MK, Schwab W, Verstappen FW, van der Plas LH, Bouwmeester HJ, Verhoeven HA. Monoterpene biosynthesis in lemon (*Citrus limon*) cDNA isolation and functional analysis of four monoterpene synthases. *Eur J Biochem*. 2002;269:3160–71.
- 41.
- Kurusu T, Kuchitsu K, Tada Y. Plant signaling networks involving  $Ca^{2+}$  and Rboh/Nox-mediated ROS production under salinity stress. *Front Plant Sci*. 2015;6:427.
- 42.
- Dahl RH, Zhang F, Alonso-Gutierrez J, Baidoo E, Batth TS, Redding-Johanson AM, Petzold CJ, Mukhopadhyay A, Lee TS, Adams PD, Keasling JD. Engineering dynamic pathway regulation using stress-response promoters. *Nat Biotechnol*. 2013;31:1039–46.

43. Sivy TL, Fall R, Rosenstiel TN. Evidence of isoprenoid precursor toxicity in *Bacillus subtilis*. *Biosci Biotechnol Biochem*. 2011;75:2376–83.
44. Cao Y, Zhang R, Liu W, Zhao G, Niu W, Guo J, Xian M, Liu H. Manipulation of the precursor supply for high-level production of longifolene by metabolically engineered *Escherichia coli*. *Sci Rep*. 2019;9:95.
45. Guan Z, Xue D, Abdallah II, Dijkshoorn L, Setroikromo R, Lv G, Quax WJ. Metabolic engineering of *Bacillus subtilis* for terpenoid production. *Appl Microbiol Biotechnol*. 2015;99:9395–406.
46. Griffin S, Wyllie SG, Markham J. Determination of octanol–water partition coefficient for terpenoids using reversed-phase high-performance liquid chromatography. *J Chromatogr A*. 1999;864:221–8.
47. Chang HC, Oriel P. Bioproduction of perillyl alcohol and related monoterpenes by isolates of *Bacillus stearothermophilus*. *J Food Sci*. 1994;59:660–2.
48. Chubukov V, Mingardon F, Schackwitz W, Baidoo EE, Alonso-Gutierrez J, Hu Q, Lee TS, Keasling JD, Mukhopadhyay A. Acute limonene toxicity in *Escherichia coli* is caused by limonene-hydroperoxide and alleviated by a point mutation in alkyl hydroperoxidase (AhpC). *Appl Environ Microbiol*. 2015;81:4690–6.
49. Ma SM, Garcia DE, Redding-Johanson AM, Friedland GD, Chan R, Batth TS, Haliburton JR, Chivian D, Keasling JD, Petzold CJ, Lee TS, Chhabra SR. Optimization of a heterologous mevalonate pathway through the use of variant HMG-CoA reductases. *Metab Eng*. 2011;13:588–97.
50. Yang J, Xian M, Su S, Zhao G, Nie Q, Jiang X, Zheng Y, Liu W. Enhancing production of bio-isoprene using hybrid MVA pathway and isoprene synthase in *E. coli*. *PLoS One*. 2012a;7:e33509.
51. Guo J, Cao Y, Liu H, Zhang R, Xian M, Liu H. Improving the production of isoprene and 1,3-propanediol by metabolically engineered *Escherichia coli* through recycling redox cofactor between the dual pathways. *Appl Microbiol Biotechnol*. 2019;103:2597–608.
52. Jongedijk E, Cankar K, Ranzijn J, van der Krol S, Bouwmeester H, Beekwilder J. Capturing of the monoterpene olefin limonene produced in *Saccharomyces cerevisiae*. *Yeast*. 2015;32:159–71.
53. Leng C, Kish JD, Kelley J, Mach M, Hiltner J, Zhang Y, Liu Y. Temperature-dependent Henry's Law Constants of atmospheric organics of biogenic origin. *J Phys Chem A*. 2013;117:10359–67.
54. Kiyota H, Okuda Y, Ito M, Hirai MY, Ikeuchi M. Engineering of cyanobacteria for the photosynthetic production of limonene from CO<sub>2</sub>. *J Biotechnol*. 2014;185:1–7.
- 55.

Vararu F, Moreno-Garcia J, Moreno J, Niculaua M, Nechita B, Zamfir C, Colibaba C, Dumitru GD, Cotea VV. Minor volatile compounds profiles of 'Aligoté' wines fermented with different yeast strains. *Not Sci Biol.* 2015;7:123–8.

56.

Davies FK, Work VH, Beliaev AS, Posewitz MC. Engineering limonene and bisabolene production in wild type and a glycogen-deficient mutant of *Synechococcus* sp. PCC 7002. *Front Bioeng Biotechnol.* 2014;2:21.

57.

Willrodt C, David C, Cornelissen S, Bühler B, Julsing MK, Schmid A. Engineering the productivity of recombinant *Escherichia coli* for limonene formation from glycerol in minimal media. *Biotechnol J.* 2014;9:1000–12.

58.

Pang Y, Zhao Y, Li S, Zhao Y, Li J, Hu Z, Zhang C, Xiao D, Yu A. Engineering the oleaginous yeast *Yarrowia lipolytica* to produce limonene from waste cooking oil. *Biotechnol Biofuels.* 2019;12:241.

59.

Cao X, Lv YB, Chen J, Imanaka T, Wei LJ, Hua Q. Metabolic engineering of oleaginous yeast *Yarrowia lipolytica* for limonene overproduction. *Biotechnol Biofuels.* 2016;9:214.

60.

Zheng Y, Liu Q, Li L, Qin W, Yang J, Zhang H, Jiang X, Cheng T, Liu W, Xu X, Xian M. Metabolic engineering of *Escherichia coli* for high-specificity production of isoprenol and prenol as next generation of biofuels. *Biotechnol Biofuels.* 2013;6:57.

61.

Brennan TC, Turner CD, Krömer JO, Nielsen LK. Alleviating monoterpene toxicity using a two-phase extractive fermentation for the bioproduction of jet fuel mixtures in *Saccharomyces cerevisiae*. *Biotechnol Bioeng.* 2012;109:2513–22.

## Figures






Figure 1

(R)-(+)-perillyl alcohol production via the MVA pathway. Enzymes are depicted in the legend.




**Figure 2**

Effect of limonene concentration on the activity of SC01. When the OD<sub>600</sub> reached 0.6, samples were induced at 30°C for 24 h using 0.2 mM IPTG and 0.1 mM (R)-(+)-limonene. Error bars: SD from three independent cultivations.




**Figure 3**

Limonene production using the SC02 strain. The enantiomeric distribution of limonene was analyzed using the Agilent Technologies 7890B GC System on a Cyclodex B column (30m×0.25mm internal diameter; film thickness=0.25µm). GC conditions were as follows: 50 °C hold, 2°C/min ramping to 160 °C; carrier: high-purity helium, linear velocity: 1 ml/min; temperature of the injector: 250 °C; split ratio: 1:20. Compounds of interest: (S)-(-)-limonene at 21.2 min and (R)-(+)-limonene at 22.02 min. The fermentation broth was mixed and centrifuged, and the organic layer was analyzed. The total production of Limonene was measured after 2 and 3 days of IPTG induction and 10% n-dodecane or DINP induction.




**Figure 4**

Relative expression levels in SC04 and SC05 engineered for (R)-(+)-perillyl alcohol production. Data was for 24 h in LB medium with 0.2 mM IPTG and 20 g/L glucose. Gene expression was calculated using the  $2^{-\Delta\Delta CT}$  system and are shown as the mean  $\pm$  SD ( $n \geq 3$ ). Identical letters indicate no significant differences ( $p < 0.05$ ).



**Figure 5**

5 Perillyl alcohol production using SC04 and SC05 strains. Total production of (R)-(+)-perillyl alcohol was measured at 72 h after induction with 0.2 mM IPTG and 10% n-dodecane or 10% DINP, Data are the means of 3 repetitions  $\pm$  SD.



**Figure 6**

Time-course of cell density (OD<sub>600</sub>), and perillyl alcohol production during fed-batch fermentation of SC04.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [supplementarymaterials0203.docx](#)